Linked Life Data

12595763

Source:http://linkedlifedata.com/resource/pubmed/id/12595763

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-2-21
pubmed:abstractText
Human immunodeficiency virus type 1 (HIV-1) Vpu protein promotes both extracellular release of viral particles and degradation of CD4 in the endoplasmic reticulum. The correlation of anti-Vpu antibody (Ab) reactivity to Vpu and AIDS disease progression was studied in 162 HIV-1/AIDS patients after they had received highly active antiretroviral therapy (HAART) for 1 year. Anti-Vpu Ab reactivity was analyzed by Western blot using a recombinant Vpu protein. Results showed that at baseline (prior to initiation of HAART), 31.5% of patients (51/162) had anti-Vpu Ab. The proportion of anti-Vpu Ab in patients with CD4 counts > or =500, 200-500 and <200/mm(3) were 40.6, 34.7 and 14.3%, respectively (chi(2) test, p < 0.05). In addition, decreasing levels of anti-Vpu Ab reactivity were significantly correlated with increasing levels of HIV-1 viral load. After receiving HAART for 1 year, 7 of 111 anti-Vpu Ab-negative patients (6.3%) seroconverted (- --> + group) and 8 of 51 anti-Vpu Ab-positive (15.7%) patients became negative (+ --> - group). Among 104 anti-Vpu Ab-negative patients, 40 were selected for analysis of the VPU gene. All of them had an intact VPU gene. Patients were further divided into four groups according to their anti-Vpu Ab serostatus and anti-HIV-1 Ab was measured. The results showed that only the anti-Vpu Ab seroconverted group (- --> +) had increased serum levels of anti-HIV-1 Abs after 1 year of HAART, while the other three groups (+ --> +, - --> - and + --> -) had decreased serum levels of anti-HIV-1 Abs after 1 year of HAART (p < 0.05). In conclusion, the presence of anti-Vpu Ab is associated with improved prognosis following HIV-1 infection, and seroconversion of anti-Vpu Ab in patients on HAART indicates significant recovery of immunity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1021-7770
pubmed:author
pubmed:copyrightInfo
Copyright 2003 National Science Council, ROC and S. Karger AG, Basel
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
266-75
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:12595763-Acquired Immunodeficiency Syndrome, pubmed-meshheading:12595763-Amino Acid Sequence, pubmed-meshheading:12595763-Anti-HIV Agents, pubmed-meshheading:12595763-Antigens, CD4, pubmed-meshheading:12595763-Antiretroviral Therapy, Highly Active, pubmed-meshheading:12595763-Blotting, Western, pubmed-meshheading:12595763-Disease Progression, pubmed-meshheading:12595763-Endoplasmic Reticulum, pubmed-meshheading:12595763-Gene Products, vpr, pubmed-meshheading:12595763-Glutathione Transferase, pubmed-meshheading:12595763-Humans, pubmed-meshheading:12595763-Immunoglobulin G, pubmed-meshheading:12595763-Molecular Sequence Data, pubmed-meshheading:12595763-Phylogeny, pubmed-meshheading:12595763-Plasmids, pubmed-meshheading:12595763-Prognosis, pubmed-meshheading:12595763-Recombinant Proteins, pubmed-meshheading:12595763-Sequence Analysis, DNA, pubmed-meshheading:12595763-Sequence Homology, Amino Acid, pubmed-meshheading:12595763-vpr Gene Products, Human Immunodeficiency Virus
pubmed:articleTitle
Antibody reactivity to HIV-1 Vpu in HIV-1/AIDS patients on highly active antiretroviral therapy.
pubmed:affiliation
AIDS Prevention and Research Center, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. arthur@ym.edu.tw
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't